BrainStorm Cell Therapeutics Inc.
335 articles with BrainStorm Cell Therapeutics Inc.
Days after President Donald Trump signed the Right-to-Try legislation there are still many uncertainties about the law.
BrainStorm Cell Therapeutics Inc. announced it has entered into a Warrant Exercise Agreement with certain holders of warrants issued in the January 8, 2015 private placement.
BrainStorm to Host Call Following President Trump's Citing of Company's ALS Treatment During "Right-to-Try" Bill Signing
BrainStorm Cell Therapeutics Inc. announced today that the company will host a "Right-to-Try" (RTT) discussion call on Thursday, June 7th at 8:15am EDT.
BrainStorm Cell Therapeutics Inc. announced today that the Company will present a corporate overview at the BIO International Convention.
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issues a statement following Congress passing the Federal "Right-to-Try" bill.
BrainStorm Announces First Quarter 2018 Financial Results and Provides Corporate and Clinical Highlights
Call Today and Webcast @ 8:30am Eastern Time Today
BrainStorm Cell Therapeutics to Participate in Movement Disorder Panel at the Neurotech Investing and Partnering Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that Ralph Kern, M.D., MHSc, Chief Operating Officer and Chief Medical Officer, will be a panelist at the 13th Annual Neurotech Investing & Partnering Conference, taking place May 1-2 in Boston, Massachusetts.
Canada-Based ALS Patients Can Be Enrolled at The University of Massachusetts.
BrainStorm Announces Formation of Scientific Advisory Board and Appoints Neuroscientist Jerold Chun, M.D., Ph.D., to Chair
BrainStorm Cell Therapeutics Inc. announced the formation of its Scientific Advisory Board (SAB) and the appointment of Jerold Chun, M.D., Ph.D., to Chair. Chun is an acclaimed neuroscientist and professor at Sanford Burnham Prebys Medical Discovery Institute with decades of expertise in degenerative disease research and neuroscience drug development.
BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017
2017 was a very productive year for BrainStorm, with significant progress and achievements across clinical, operational and financial fronts.
BrainStorm Cell Therapeutics Appoints Senior Kite Executive, Anthony Polverino, Ph.D., to Board of Directors
BrainStorm announced today the appointment of Anthony Polverino, Ph.D., to its board of directors. Dr. Polverino is a highly accomplished senior biopharma executive with more than 25 years' industry experience in drug research and development.
This approval paves the way for the company's application to the Israel MoH for the treatment of ALS patients in Israel for a fee, under the newly introduced Hospital Exemption regulation.
BrainStorm today issued a Letter to Shareholders from its President and CEO, Chaim Lebovits
BrainStorm's Abstracts on Phase II NurOwn Biomarkers Accepted for Presentation at the International Symposium on ALS/MND in Boston
The posters will feature the analyses of CHIT-1 and microRNAs in the cerebrospinal fluid of ALS patients participating in the Phase II study, as biomarkers to evaluate ALS disease progression and NurOwn treatment response.
The publication shows that NurOwn - mesenchymal stem cells induced to secrete neurotrophic factors - have both an enhanced secretion of NTFs as well as a distinct miRNA expression profile that distinguishes them from their MSCs of origin.
Mr. Rubin will be responsible for all corporate finance and accounting activities for BrainStorm.
BrainStorm Expands its Patent Portfolio to Include a New U.S. Patent for Iis NurOwn® Technology for Parkinson's Disease And ALS
BrainStorm announced that it has received Notice of Allowance from the U.S. Patent Office for U.S. Patent Application No.: 14/173,846.
BrainStorm announced financial results for the third quarter ending September 30, 2017.
BrainStorm Cell Therapeutics today announced that the first patients have been enrolled in the Phase 3 clinical trial of NurOwn for the treatment of amyotrophic lateral sclerosis (ALS) at the Massachusetts General Hospital and UC Irvine Medical Center in California.
BrainStorm Cell To Announce Third Quarter Financial Results And Provide Corporate Updates On Tuesday, October 17